Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Grogl

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
The American Journal of Tropical Medicine and Hygiene|June 6, 2014
In responseMax Grogl, Nestor Sosa, Mara Kreishman-Deitrick
Plos Neglected Tropical Diseases|April 5, 2013
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasisPiero Olliaro, Michel Vaillant, Byron Arana, et al.
The American Journal of Tropical Medicine and Hygiene|February 8, 2013
Drug discovery algorithm for cutaneous leishmaniasisMax Grogl, Mark Hickman, William Ellis, et al.
The American Journal of Tropical Medicine and Hygiene|October 28, 2015
Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major AmastigotesMozna Khraiwesh, Susan Leed, Norma Roncal, et al.
The American Journal of Tropical Medicine and Hygiene|July 24, 2002
Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot studyJaime M Soto, Julia T Toledo, Patricia Gutierrez, et al.
Plos Neglected Tropical Diseases|September 12, 2014
Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasisAnny Fortin, Diana P Caridha, Susan Leed, et al.
BMC Research Notes|February 28, 2023
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trialAlejandro Llanos-Cuentas, Alvaro Schwalb, Juan Luis Quintana, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2017
Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered <i>In Vivo</i> Screening Paradigm for Development of Drugs To Treat Cutaneous LeishmaniasisDiana Caridha, Sandi Parriot, Thomas H Hudson, et al.
The American Journal of Tropical Medicine and Hygiene|March 27, 2013
An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolinesPeng Zhang, Xiugong Gao, Hiroshi Ishida, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2013
Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasisWilliam R Ravis, Alejandro Llanos-Cuentas, Nestor Sosa, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
The American Journal of Tropical Medicine and Hygiene|June 6, 2014
In responseMax Grogl, Nestor Sosa, Mara Kreishman-Deitrick
Plos Neglected Tropical Diseases|April 5, 2013
Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasisPiero Olliaro, Michel Vaillant, Byron Arana, et al.
The American Journal of Tropical Medicine and Hygiene|February 8, 2013
Drug discovery algorithm for cutaneous leishmaniasisMax Grogl, Mark Hickman, William Ellis, et al.
The American Journal of Tropical Medicine and Hygiene|October 28, 2015
Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major AmastigotesMozna Khraiwesh, Susan Leed, Norma Roncal, et al.
The American Journal of Tropical Medicine and Hygiene|July 24, 2002
Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot studyJaime M Soto, Julia T Toledo, Patricia Gutierrez, et al.
Plos Neglected Tropical Diseases|September 12, 2014
Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasisAnny Fortin, Diana P Caridha, Susan Leed, et al.
BMC Research Notes|February 28, 2023
Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trialAlejandro Llanos-Cuentas, Alvaro Schwalb, Juan Luis Quintana, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2017
Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered <i>In Vivo</i> Screening Paradigm for Development of Drugs To Treat Cutaneous LeishmaniasisDiana Caridha, Sandi Parriot, Thomas H Hudson, et al.
The American Journal of Tropical Medicine and Hygiene|March 27, 2013
An in vivo drug screening model using glucose-6-phosphate dehydrogenase deficient mice to predict the hemolytic toxicity of 8-aminoquinolinesPeng Zhang, Xiugong Gao, Hiroshi Ishida, et al.
Antimicrobial Agents and Chemotherapy|July 24, 2013
Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasisWilliam R Ravis, Alejandro Llanos-Cuentas, Nestor Sosa, et al.
Pageof 3